Literature DB >> 22429281

Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort.

Steen Rosthøj1, Jukka Rajantie, Iris Treutiger, Bernward Zeller, Ulf Tedgård, Jan-Inge Henter.   

Abstract

AIM: To describe the clinical course, morbidity and platelet recovery in an unselected Nordic cohort of children with chronic Immune Thrombocytopenic Purpura (ITP).
METHODS: Prospective 5-year follow-up of 96 children with ITP lasting more than 6 months, with reporting of hospital admissions, severity of bleeding episodes and stabilization of platelet counts above 20, 50 and 150 × 10(9) /L.
RESULTS: The estimated 5-year recovery rate was 52%; exclusion of 12 splenectomized children did not change the estimate. Events eliciting admission to hospital occurred in 39 (41%). Major haemorrhages occurred in eight children (8%), including a nonfatal intracranial haemorrhage in one child (1%). The overall admission rate was 0.4/year of thrombocytopenia, decreasing during follow-up as thrombocytopenia converted to milder degrees. Early recovery within 2 years of diagnosis occurred in 35%, was associated with low morbidity and was more likely in young children with abrupt onset of symptoms.
CONCLUSION: In a Nordic cohort of children with chronic ITP, one half had recovered 5 years after diagnosis, more than half never required hospitalization and <10% experienced serious bleeding episodes, always with a platelet count <20 × 10(9) /L. Aggressive management can be restricted to the minority of children with continuing severe thrombocytopenia and frequent, clinically significant bleeding events.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 22429281     DOI: 10.1111/j.1651-2227.2012.02671.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  Psychiatric Disorders and Quality of Life in Egyptian Patients with Chronic Immune Thrombocytopenic Purpura: A Single Center Study.

Authors:  Sohier Yahia; Yahya Wahba; Abdel-Hady El-Gilany; Suzy Abdelmabood; Mohamed Adel El-Hadidy; Ahmad Darwish; Ahmed K Mansour
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-11       Impact factor: 0.900

Review 2.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

3.  Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.

Authors:  Motohiro Kato; Katsuyoshi Koh; Akira Kikuchi; Ryoji Hanada
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

4.  Association of CD4(+)CD25(+)FoxP3(+) regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura.

Authors:  Bo Ra Son; Ji Yoon Kim
Journal:  Korean J Pediatr       Date:  2015-05-22

5.  Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience.

Authors:  Ye Jee Shim; Uk Hyun Kim; Jin Kyung Suh; Kun Soo Lee
Journal:  Blood Res       Date:  2014-09-25

6.  Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Authors:  Michael D Tarantino; James B Bussel; Victor S Blanchette; Donald Beam; John Roy; Jenny Despotovic; Ashok Raj; Nancy Carpenter; Bhakti Mehta; Melissa Eisen
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

7.  Incidence and outcomes of refractory immune thrombocytopenic purpura in children: a retrospective study in a single institution.

Authors:  Masataka Ito; Hiroshi Yagasaki; Koji Kanezawa; Katsuyoshi Shimozawa; Maiko Hirai; Ichiro Morioka
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

8.  High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

Authors:  Chae Young Kim; Eun Hye Lee; Hoi Soo Yoon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

Review 9.  Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.

Authors:  John D Grainger; Thomas Kühne; Jane Hippenmeyer; Nichola Cooper
Journal:  Ann Hematol       Date:  2021-07-26       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.